Citeline Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade

Articles mentioned in this podcast: US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC OTC Switch For Daily Oral Contraceptive Brandished In Senate Health Care Policy Duel Barriers To US OTC Emergency Contraceptive Sales Remain Despite Court Rebuke Of Restrictions Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers Dual Rx/OTC Status In US ‘Additional Condition’ Switch Proposal: Necessary Or Questionable? US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights With Roe v. Wade In Rearview, What’s Next For Women’s Health Telemedicine Among Sticky Wickets As Uncertainty Abounds Post-Roe v. Wade Period-Tracking Apps Should Safeguard Data, Reassure Customers In Post-Roe Era